Abstract: Systems, computer program products, and methods are described herein for large scale data extraction and processing. The method includes receiving a transmission request. The transmission request indicates two or more accounts for which one or more account statements are to be retrieved. The method also includes selecting a first retrieval set of the two or more accounts. A first retrieval set size of the first retrieval set is based on a first expected network capacity. The method further includes causing a retrieval of one or more account statements associated with first retrieval set. The method still further includes selecting a second retrieval set of the two or more accounts. A second retrieval set size of the second retrieval set is based on a second expected network capacity. The method includes causing a retrieval of one or more account statements associated with the second retrieval set.

Abstract: Systems, computer program products, and methods are described herein for large scale data extraction and processing. The method includes receiving a transmission request. The transmission request indicates two or more accounts for which one or more account statements are to be retrieved. The method also includes selecting a first retrieval set of the two or more accounts. A first retrieval set size of the first retrieval set is based on a first expected network capacity. The method further includes causing a retrieval of one or more account statements associated with first retrieval set. The method still further includes selecting a second retrieval set of the two or more accounts. A second retrieval set size of the second retrieval set is based on a second expected network capacity. The method includes causing a retrieval of one or more account statements associated with the second retrieval set.

Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for automating data validation. The system is configured to receive the initial data set in the first data structure from a network of distributed servers; transform the initial data set into an expected data set having the second data structure using a first mapping logic; use the expected data set to validate a converted data set that was generated by converting the initial data set into the second data structure using a second mapping logic; and transmit control signals configured to cause a user device associated with the user to receive a notification indicating that the match is within the pre-determined tolerance level.

Abstract: The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.

Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for automating data validation. The system is configured to receive the initial data set in the first data structure from a network of distributed servers; transform the initial data set into an expected data set having the second data structure using a first mapping logic; use the expected data set to validate a converted data set that was generated by converting the initial data set into the second data structure using a second mapping logic; and transmit control signals configured to cause a user device associated with the user to receive a notification indicating that the match is within the pre-determined tolerance level.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: An energy absorbing tubular structure is formed of a molded or extruded polymer. The tube has a quadrangular cross-section with rounded corners. The walls of tube are corrugated with alternating convex and concave corrugations surfaces having a continuous constant radius, preferably with no flat spots. The corrugated walls have a constant thickness. The corrugations progressively deform during impact thereby providing a near perfect square wave force vs. deflection energy absorption curve at any predetermined nearly constant force level. The tube may be filled with polymer foam to vary the impact performance of the structure.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: An energy absorbing tubular structure is formed of a molded or extruded polymer. The tube has a quadrangular cross-section with rounded corners. The walls of tube are corrugated with alternating convex and concave corrugations surfaces having a continuous constant radius, preferably with no flat spots. The corrugated walls have a constant thickness. The corrugations progressively deform during impact thereby providing a near perfect square wave force vs. deflection energy absorption curve at any predetermined nearly constant force level. The tube may be filled with polymer foam to vary the impact performance of the structure.